Modulation of Interleukin-6/Interleukin-6 Receptor Cytokine Loop in the Treatment of Multiple Myeloma

References

• Alexanian R., Dimipoulos M. The treatment of multiple myeloma. N. Engl. J. Med. 1994; 330: 484–489
   PubMed Web of Science ®Google Scholar
• Gregory W. M., Richard M. A., Malpas J. S. Combination chemotherapy versus melphalan and prednisone in the treatment of multiple myeloma: An overview of published trials. J. Clin. Oncol. 1992; 10: 334–342
   PubMed Web of Science ®Google Scholar
• Jagannath S., Vesole D. H., Glenn L., Crowely J., Barlogie B. Low risk intensive therapy for multiple myeloma with combined autologous bone marrow and blood stem cell support. Blood 1992; 80: 1666–1672
   PubMed Web of Science ®Google Scholar
• Fermand J-P., Chevert S., Ravaud P., et al. High-dose chemoradiotherapy and autologous blood stem cell transplantation in multiple myeloma: Results of a phaae II trial involving 63 patients. Blood 1993; 82: 2005–2009
   PubMed Web of Science ®Google Scholar
• Anderson K. C., Barut B. A., Ritz J., et al. Monoclonal antibody-purged autologous bone marrow transplantation therapy for multiple myeloma. Blood 1991; 77: 712–720
   PubMed Web of Science ®Google Scholar
• Attal M., Harousseau J.-L., Stoppa A.-M., et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N. Engl. J. Med. 1996; 335: 91–97
   PubMed Web of Science ®Google Scholar
• Barlogie B., Epstein J., Selvanayagain P., Alexanian R. Plasma cell myeloma-New biological insights and advances in therapy. Blood 1989; 73: 865–879
   PubMed Web of Science ®Google Scholar
• Mandelli F., Avviaati G., Tribalto M. Biology and treatment of multiple myeloma. Curr. Opinion in Oncol. 1992; 4: 73–86
   PubMedGoogle Scholar
• Klein B., Zhang X.-G., Lu Z.-Y., Bataille R. Interleukin-6 in human multiple myeloma. Blood 1995; 85: 863–872
   PubMed Web of Science ®Google Scholar
• Chen Y.-H., Desai P., Shiao R.-T., Lavelle D., Haleem A., Chen J. Inhibition of myeloma cell growth by dexamethasone and all-trans retinoic acid: Synergy through modulation of interleukin-6 autocrine loop at multiple sites. Blood 1996; 87: 314–323
   PubMed Web of Science ®Google Scholar
• Kawano M., Hirano T., Matsuda T., et al. Autocrine generation and requirement of BSF-2/IL-6 for human myelomas. Nature 1988; 332: 83–85
   PubMed Web of Science ®Google Scholar
• Anderson K. C., Jones R. M., Morimoto C., Leavitt P., Barut B. A. Response patterns of purified myeloma cells to hematopoietic growth factors. Blood 1989; 73: 1915–1924
   PubMed Web of Science ®Google Scholar
• Freeman G. J., Freeman A. S., Rabinowe S. N., et al. Interleukin 6 gene expression in normal and neoplastic B-cells. J. Clin. Invest. 1989; 83: 1512–1518
   PubMed Web of Science ®Google Scholar
• Schwab G., Siegall C. B., Aarden L. A., Neckers L. M., Nordan R. P. Characterization of an interleukin-6-mediated autocrine growth loop in the human myeloma cell line, U266. Blood 1991; 77: 587–593
   PubMed Web of Science ®Google Scholar
• Levy Y., Tsapis A., Brouet J.-C. Interleukin-6 antisense oligonucleotides inhibit the growth of human myeloma cell lines. J. Clin. Invest. 1991; 88: 696–699
   PubMed Web of Science ®Google Scholar
• Portier M., Rajzbaum G., Zhang X.-G., et al. In vivo interleukin 6 gene expression in the tumoral environment in multiple myeloma. Eur. J. Immunol. 1991; 21: 1759–1762
   PubMed Web of Science ®Google Scholar
• Klein B., Zhang X.-G., Jourdan M., et al. Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6. Blood 1989; 73: 517–526
   PubMed Web of Science ®Google Scholar
• Akira S., Taga T., Kishimoto T. Interleukin-6 in biology and medicine. Adv. Immunol. 1993; 54: 1–78
   PubMed Web of Science ®Google Scholar
• Lokhorst H. M., Lamme T., de Smet M., et al. Primary tumor cells of myeloma patients induce interleukin-6 secretion in long-term bone marrow cultures. Blood 1994; 84: 2269–2277
   PubMed Web of Science ®Google Scholar
• Bataille R., Jourdan M., Zhang X.-G., Klein B. Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias. J. Clin. Invest. 1989; 84: 2008–2011
   PubMed Web of Science ®Google Scholar
• Reibnegger G., Krainer M., Herold M., Ludwig H., Wachter H., Huber H. Predictive value of interleukin-6 and neopterin in patients with multiple myeloma. Cancer Res. 1991; 51: 6250–6253
   PubMed Web of Science ®Google Scholar
• Bergui L., Schena M., Gaidano G., Riva M., Caligaris-Cappio F. Interleukin 3 and interleukin 6 synergisti-cally promote the proliferation and differentiation of malignant plasma cell precursors in multiple myeloma. J. Exp. Med. 1989; 170: 613–618
   PubMed Web of Science ®Google Scholar
• Caligaris-Cappio F., Bergui L., Gregoretti M. G., et al. Role of bone marrow stromal cells in the growth of human multiple myeloma. Blood 1991; 77: 2688–2693
   PubMed Web of Science ®Google Scholar
• Zhang X.-G., Bataille R., Jourdan M., Saeland S., Banchereau J., Mannoni P. Granulocyte-macrophage colony-stimulating factor synergies with interleukin-6 in supporting the proliferation of human myeloma cells. Blood 1990; 76: 2599–2605
   PubMed Web of Science ®Google Scholar
• Lu Z. Y., Zhang X. G., Rodriguez C., et al. Interleukin-10 is a proliferation factor but not a differentiation factor but not a differentiation factor for human myeloma cells. Blood 1995; 85: 2521–2527
   PubMed Web of Science ®Google Scholar
• Kishimoto T., Akira S., Narazaki M., Taga T. Interleukin-6 family of cytokines and gp130. Blood 1995; 86: 1243–1254
   PubMed Web of Science ®Google Scholar
• Pelliniemi T.-T., Irjala K., Mattila K., et al. lmmunoreactive interleukin-6 and acute phase proteins as prognostic factors in multiple myeloma. Blood 1995; 85: 765–771
   PubMed Web of Science ®Google Scholar
• Chen Y.-H., Magalhaes M. C. Hypoalbuminemia in patients with multiple myeloma. Arch. Intern. Med. 1990; 150: 605–610
   PubMed Web of Science ®Google Scholar
• Ohtani K., Ninomiya H., Hasegawa Y., et al. Clinical significance of elevated soluble interleukin-6 receptor levels in the sera of patients with plasma cell dyscrasias. Brit. J. Haematol. 1995; 91: 116–120
   PubMed Web of Science ®Google Scholar
• Klein B., Wijdenes J., Zhang X.-G., et al. Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia. Blood 1991; 78: 1198–1204
   PubMed Web of Science ®Google Scholar
• Manolagas S. C., Jilka R. L. Bone marrow, cytokines, and bone remodeling. N. Engl. J. Med. 1995; 332: 305–311
   PubMed Web of Science ®Google Scholar
• Bataille R., Chappard D., Marcelli C., et al. Recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma. J. Clin. Invest. 1991; 88: 62–66
   PubMed Web of Science ®Google Scholar
• Bataille R., Chappard D., Klein B. Mechanisms of bone lesions in multiple myeloma. Hematol. Oncol. Clin. North. Amer. 1992; 6: 285–295
   PubMed Web of Science ®Google Scholar
• Mundy G., Raisz L. G., Cooper R. A., Schechter G. P., Salmon S. E. Evidence for the secretion of an osteo-clast stimulating factor in myeloma. N. Engl. J. Med. 1974; 291: 1041–1046
   PubMed Web of Science ®Google Scholar
• Pulkki K., Pelliniemi T.-T., Rajamaki A., Tienhaara A., Laakso M., Lahtinen R. Soluble interleukin-6 receptor as a prognostic factor in multiple myeloma. Brit. J. Haematol. 1996; 92: 370–374
   PubMed Web of Science ®Google Scholar
• Gaillard J.-P., Bataille R., Brailly H., et al. Increased and highly stable levels of functional soluble interleukin-6 receptor in sera of patients with monoclonal gammopathy. Eur. J. Immunol. 1993; 23: 820–824
   PubMed Web of Science ®Google Scholar
• Tamura T., Udagawa N., Takahashi N., et al. Soluble interleukin-6 receptor triggers osteoclast formation by interleukin-6. Proc. Natl. Acad. Sci. USA 1993; 90: 11924–11928
   PubMed Web of Science ®Google Scholar
• Schwabe M., Brini A. T., Bosco M. C., et al. Disruption by interferon-α of an autocrine interleukin-6 growth loop in IL-6-dependent U266 myeloma cells by homologous and heterologous down-regulation of the IL-6 receptor α- and β-chains. J. Clin. Invest. 1994; 94: 2317–2325
   PubMed Web of Science ®Google Scholar
• Anthes J. C., Zhan A., Gilchrist H., Egan R. W., Siegel M. I., Billah M. M. Interferon-α down-regulates the interleukin-6 receptor in a human myeloma cell line. U266. Biochem. J. 1995; 309: 175–180
   PubMed Web of Science ®Google Scholar
• Lasfar A., Wietzerbin J., Billard C. Differential regulation of interleukin-6 receptors by interleukin-6 and interferons in multiple myeloma cell lines. Eur. J. Immunol. 1994; 24: 124–130
   PubMed Web of Science ®Google Scholar
• Tanaka H., Tanabe O., Iwato K., et al. Sensitive inhibitory effect of interferon-alpha on M-protein secretion on human myeloma cells. Blood 1989; 74: 1718–1722
   PubMed Web of Science ®Google Scholar
• Jernberg-Wiklund H., Pettersson M., Nilsson K. Recombinant interferon-γ inhibits the growth of IL-6-dependent human multiple myeloma cell lines in vitro. Eur. J. Haematol. 1991; 46: 231–239
   PubMed Web of Science ®Google Scholar
• Portier M., Zhang X.-G., Caron E., Lu Z.-Y., Bataille R., Klein B. γ-interferon in multiple myeloma: Inhibition of interleukin-6 (IL-6)-dependent myeloma cell growth and downregulation of IL-6-receptor expression in vitro. Blood 1993; 81: 3076–3082
   PubMed Web of Science ®Google Scholar
• Palumbo A., Battaglio S., Napoli P., et al. Recombinant interferon-γ inhibits the in vitro proliferation of human myeloma cells. Brit. J. Haematol. 1994; 86: 726–732
   PubMed Web of Science ®Google Scholar
• Palumbo A., Bruno B., Boccadoro M., Pileri A. Interferon-γ in multiple myeloma. Leukemia and Lymphoma 1995; 18: 215–219
   PubMed Web of Science ®Google Scholar
• McIntyre O. S., Pajak T. F., Kyle R. A., Cornwell G. G., III, Leone L. Response rate and survival in myeloma patients receiving prednisone alone. Med. Pediatr. Oncol. 1985; 13: 239–243
   PubMedGoogle Scholar
• Ishikawa H., Tanaka H., Iwato K., et al. Effect of glucocorticoids on the biologic activities of myeloma cells: Inhibition of interleukin-Iβ osteoclast activating factor-induced bone resorption. Blood 1991; 75: 715–720
   Web of Science ®Google Scholar
• Gomi M., Moriwaki K., Katagiri S., Kurata Y., Thompson E. B. Glucocorticoid effects on myeloma cells in culture: Correlation of growth inhibition with induction of glucocorticoid receptor messenger RNA. Cancer Res. 1990; 50: 1873–1878
   PubMed Web of Science ®Google Scholar
• Shiao R.-T., Miglietta L., Khera S. Y., Wolfson A., Freter C. E. Dexamethasone and suramin inhibit cell proliferation and interleukin-6-mediated immunoglobulin secretion in human lymphoid and multiple myeloma cell lines. Leukemia and Lymphoma 1995; 17: 484–494
   Web of Science ®Google Scholar
• Shiao R.-T., McLeskey S. B., Khera S. Y., Wolfson A., Freter C. E. Mechanisms of inhibition of IL-6-mediated immunoglobulin secretion by dexamethasone and suramin in human lymphoid and myeloma cell lines. Leukemia and Lymphoma 1996; 21: 293–303
   PubMed Web of Science ®Google Scholar
• Hardin J., MacLeod S., Girgorieva I., et al. Interleukin-6 prevents dexamethasone-induced myeloma cell death. Blood 1994; 84: 3063–3070
   PubMed Web of Science ®Google Scholar
• Moali P. A., Pillay S., Weiner D., Leikin R., Rosen S. T. A mechanism of resistance to glucocorticoids in multiple myeloma: Transient expression of a truncated glucocorticoid receptor mRNA. Blood 1992; 79: 213–222
   PubMed Web of Science ®Google Scholar
• Ray A., Zhang D.-H., Siegel M. D., Ray P. Regulation of interleukin-6 gene expression by steroids. Interleukin-6 Type Cytokines, A. Mackiewicz, A. Koj, P. B. Sehgal. Acad. Sci., Ann., NY 1995; vol. 762: 79–88
   Google Scholar
• Sidell N., Taga T., Hirano T., Kishimoto T., Saxon A. Retinoic acid-induced growth inhibition of a human myeloma cell line via down-regulation of IL-6 receptors. J. Immunol. 1991; 146: 3809–3814
   PubMed Web of Science ®Google Scholar
• Levy Y., Labaume S., Colombel M., Brouet J. C. Retinoic acid modulates the in vivo and in vitro growth of IL-6 autocrine human myeloma cell lines via induction of apoptosis. Clin. Exp. Immunol. 1996; 104: 167–172
   PubMed Web of Science ®Google Scholar
• Ogata A., Nishimoto N., Shima Y., Yoshizaki K., Kishimoto T. Inhibitory effect of all-trans retinoic acid on the growth of freshly isolated myeloma cells via interference with interleukin-6 signal transduction. Blood 1994; 84: 3040–3046
   PubMed Web of Science ®Google Scholar
• Pulkki K., Neva M., Koskela K., Ollikainen H., Remes K., Pelliniemi T.-T. IL-6 receptor-mediated growth inhibition by all-trans retinoic acid but not by interferon-α in human myeloma cells. Interleukin-6 Type Cytokines, A. Mackiewicz, A. Koj, P. B. Sehgal. Acad. Sci., Ann., N. Y. 1995; vol. 762: 457–458
   Google Scholar
• Strassmann G., Fong M., Freter C. E., Windsor D., D'Alessandro F., Nordan R. P. Suramin interferes with interleukin-6 receptor binding in vitro and inhibit colon-26 mediated experimental cancer cachexia in vivo. J. Clin. Invest. 1993; 92: 2152–2159
   PubMed Web of Science ®Google Scholar
• Taylor C. W., Lui R., Salmon S. E. Effects of suramin on in vitro growth of fresh human tumors. J. Natl. Cancer Inst. 1992; 84: 489–494
   PubMed Web of Science ®Google Scholar
• Stein C. A. Suramin: a novel antineoplastic agent with multiple potential mechanisms of action. Cancer Res 1993; 53: 2239–2248
   PubMed Web of Science ®Google Scholar
• Suzuki H., Yasukawa K., Saito T., et al. Anti-human interleukin-6 receptor antibody inhibits human myeloma growth in vivo. Eur. J. Immimol. 1992; 22: 1989–1993
   PubMed Web of Science ®Google Scholar
• Sporeno E., Savino R., Ciapponi L., et al. Human interleukin-6 receptor super-antagonists with high potency and wide spectrum on multiple myeloma cells. Blood 1996; 87: 4510–4519
   PubMed Web of Science ®Google Scholar
• Demartis A., Bernassola F., Savino R., Melino G., Ciliberto G. Interleukin 6 receptor superantagonists are potent inducers of human multiple myeloma cell death. Cancer Res. 1996; 56: 4213–4218
   PubMed Web of Science ®Google Scholar
• Morphological, biochemical, and flow cytometric assays of apoptosis. Curr. Protocols in Immunol, J. E. Coligan, A. M. Kruisbeek, D. M. Margulies, E. M. Shevach, W. Strober. John Wiley and Sons, Inc. 1991; 3.17.1–3.17.14
   Google Scholar
• Kumar R., Pelletier D. Augmentation of interferon-mediated growth inhibitory and gene inducing responses of human hematopoietic tumor cell lines. Proc. Am. Asso. Cancer Res 1992; 33: 74, (abstr.)
   Google Scholar
• Siegel D., Niesvizky R., Miller W. H., Jr., Busquets X., Kumar R., Michaeli J. All trans retinoic acid (ATRA) and interferonα (INFα) synergistically inhibit myeloma cell growth and induce retinoic acid receptor α (RARα) expression. Blood 1992; 80(suppl.)121a, (abstr.)
   PubMedGoogle Scholar
• Alexanian R., Dimopoulos M. A., Delasalle K., Barlogie B. Primary dexamethasone treatment of multiple myeloma. Blood 1992; 80: 887–890
   PubMed Web of Science ®Google Scholar
• Salmon S. E., Croweley J. J., Grogan T. M., Finley P., Pugh R. P., Barlogie B. Combination chemotherapy, glucocorticoids, and interferon alfa in the treatment of multiple myeloma: A southwest oncology group study. J. Clin Oncol. 1994; 12: 2405–2414
   PubMed Web of Science ®Google Scholar
• Cooper M. R. A review of the clinical studies of alpha-interferon in the management of multiple myeloma. Sem. Oncol. 1991; 18(suppl 7)18–29
   PubMedGoogle Scholar
• Cooper M. R., Dear K., McIntyre O. R., et al. A randomized clinical trial comparing melphalan/prednisone with or without interferon alfa-2b in newly diagnosed patients with multiple myeloma: A cancer and leukemia group B study. J. Clin. Oncol. 1993; 11: 155–110
   PubMed Web of Science ®Google Scholar
• Oken M. M., Kyle R. A., Greipp P. R., et al. Possible survival with chemotherapy plus interferon (rhINF α 2) in the treatment of multiple myeloma. Proc. Am. Soc. Clin. Oncol. 1992; 11: 358, (abstr.)
   Google Scholar
• Osterborg A., Bjokholm M., Bjoreman M., et al. Natural interferon-α in combination with melphalan/ prednisone versus melphalan/prednisone in the treatment of multiple myeloma stages II and III: A randomized study from the myeloma group of central Sweden. Blood 1993; 81: 1428–1434
   PubMed Web of Science ®Google Scholar
• Mandelli F., Avvisati G., Amadori S., et al. Maintenance treatment with recombinant interferon alfa-2b in patients with multiple myeloma responding to conventional induction chemotherapy. N. Engl. J. Med. 1990; 322: 1430–1434
   PubMed Web of Science ®Google Scholar
• Browman G. P., Bergsagel D., Sicheri D., et al. Randomized trial of interferon maintenance in multiple myeloma: A study of the national cancer institute of Canada clinical trails group. J. Clin. Oncol. 1995; 13: 2354–2360
   PubMed Web of Science ®Google Scholar
• Niesvizky R., Siegel D. S., Busquets X., et al. Hypercalcemia and increased serum interleukin-6 levels induced by all-trans retinoic acid in patients with multiple myeloma. Brit. J. Haematol. 1995; 89: 217–218
   PubMed Web of Science ®Google Scholar
• Vesole D., Kornbluth J., Jagannath S., et al. Biological response modifiers (BRM) in refractory multiple myeloma (MM): Lack of clinical efficacy of recombinant human interleukin-4 (rhIL-4) and all-trans retinoic acid (ATRA). Blood 1993; 82(suppl)263a, (abstr.)
   Google Scholar
• Musto P., Falcone A., Sajeva M. S., D'Arena G., Bonini A., Carotenuto M. All-trans retinoic acid for advanced multiple myeloma. Blood 1994; 85: 3769–3770
   Web of Science ®Google Scholar
• Musto P., Sajeva M. R., Falcone A., et al. In vivo effects of all-trans retinoic acid (ATRA), as single agent or in association with alfa-interferon (INF) and high dose dexamethasone (HDDEX), in patients with advanced multiple myeloma (MM). Haematologica (Pavia). 4th Cong. Italian Soc. Exp. Hematol. 1996, (abstr.)
   Google Scholar
• Bataille R., Barlogie B., Lu Z. Y., et al. Biologic effects on anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma. Blood 1995; 86: 685–691
   PubMed Web of Science ®Google Scholar
• Chen Y., Feng X.-X., Hagen K. Usefulness of flow cytometric detection of cell surface interleukin-6 receptors in human myeloma cell lines. Clin. Lab. Haematol. 1996; 18: 161–169
   PubMedGoogle Scholar